All In Biotech

Drug Trial Radar · NCT05045248

Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Sep 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Jun 1, 2020

Primary completion

Apr 15, 2021

Study completion Apr 15, 2021

Sponsor

Lead sponsor
American University of Beirut Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is aimed at assessing the efficacy of Apraclonidine eye drops in the treatment of ptosis secondary to myasthenia gravis.

Conditions

  • Myasthenia Gravis
  • Ocular Myasthenia Gravis

Interventions

  • Apraclonidine Hcl 0.5% Oph SolnDrug

    Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in palpebral fissure height (PF)Time frame: Before administration, at 1, 5, 30, and 60 minutes after administration
  2. Change in marginal reflex distance-1 (MRD1)Time frame: Before administration, at 1, 5, 30, and 60 minutes after administration
  3. Change in marginal reflex distance-2 (MRD2)Time frame: Before administration, at 1, 5, 30, and 60 minutes after administration
  4. Change in levator function (LF)Time frame: Before administration, at 1, 5, 30, and 60 minutes after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • American University of Beirut Medical Center

    Beirut, Lebanon

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.